Evaluation of diagnostic and treatment approaches to acute dyspnea in a palliative care setting among medical doctors with different educational levels.
Cancer
Case report
Dyspnea
Medical doctors
Palliative care
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
29
10
2021
accepted:
17
03
2022
pubmed:
27
3
2022
medline:
31
5
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
Dyspnea is common in patients with advanced cancer. Diagnostic procedures in patients with dyspnea are mandatory but often time-consuming and hamper rapid treatment of the underlying refractory symptoms. Opioids are the first-line drugs for the treatment of refractory dyspnea in palliative care patients with advanced lung cancer. To evaluate the knowledge levels of medical doctors with different educational levels on the diagnosis of and treatment options for dyspnea in patients with advanced lung cancer in a palliative care setting, a case report and survey were distributed to physicians at the University Hospital Krems, describing acute dyspnea in a 64-year-old stage IV lung cancer patient. A total of 18 diagnostic and 22 therapeutic options were included in the survey. The physicians were asked to suggest and rank in order of preference their diagnosis and treatment options. Statistical analyses of the data were performed, including comparison of the responses of the senior doctors and the physicians in training. A total of 106 surveys were completed. The respondents were 82 senior physicians and 24 physicians in training (response rates of 86% and 80%, respectively). Regarding diagnostic investigations, inspection and reading the patient's chart were the most important diagnostic tools chosen by the respondents. The choices of performing blood gas analysis (p = 0.01) and measurement of oxygen saturation (p = 0.048) revealed a significant difference between the groups, both investigations performed more frequently by the physicians in training. As for non-pharmacological treatment options, providing psychological support was one of the most relevant options selected. A significant difference was seen in choosing the option of improving a patient's position in relation to level of training (65.9% senior physicians vs. 30.4% physicians in training, p = 0.04). Regarding pharmacological treatment options, oxygen application was the most chosen approach. The second most frequent drug chosen was a ß-2 agonist. Only 9.8% of the senior physicians and 8.7% of the physicians in training suggested oral opioids as a treatment option, whereas intravenous opioids were suggested by 43.9% of the senior physicians and 21.7% of the physicians in training (p = 0.089). For subcutaneous application of opioids, the percentage of usage was significantly higher for the physicians in training than for the senior physicians (78.3% vs. 48.8%, p = 0.017, respectively). The gold standard treatment for treating refractory dyspnea in patients with advanced lung cancer is opioids. Nevertheless, this pharmacological treatment option was not ranked as the most important. Discussing hypothetical cases of patients with advanced lung cancer and refractory dyspnea with experienced doctors as well as doctors at the beginning of their training may help improve symptom control for these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Dyspnea is common in patients with advanced cancer. Diagnostic procedures in patients with dyspnea are mandatory but often time-consuming and hamper rapid treatment of the underlying refractory symptoms. Opioids are the first-line drugs for the treatment of refractory dyspnea in palliative care patients with advanced lung cancer.
METHODS
METHODS
To evaluate the knowledge levels of medical doctors with different educational levels on the diagnosis of and treatment options for dyspnea in patients with advanced lung cancer in a palliative care setting, a case report and survey were distributed to physicians at the University Hospital Krems, describing acute dyspnea in a 64-year-old stage IV lung cancer patient. A total of 18 diagnostic and 22 therapeutic options were included in the survey. The physicians were asked to suggest and rank in order of preference their diagnosis and treatment options. Statistical analyses of the data were performed, including comparison of the responses of the senior doctors and the physicians in training.
RESULTS
RESULTS
A total of 106 surveys were completed. The respondents were 82 senior physicians and 24 physicians in training (response rates of 86% and 80%, respectively). Regarding diagnostic investigations, inspection and reading the patient's chart were the most important diagnostic tools chosen by the respondents. The choices of performing blood gas analysis (p = 0.01) and measurement of oxygen saturation (p = 0.048) revealed a significant difference between the groups, both investigations performed more frequently by the physicians in training. As for non-pharmacological treatment options, providing psychological support was one of the most relevant options selected. A significant difference was seen in choosing the option of improving a patient's position in relation to level of training (65.9% senior physicians vs. 30.4% physicians in training, p = 0.04). Regarding pharmacological treatment options, oxygen application was the most chosen approach. The second most frequent drug chosen was a ß-2 agonist. Only 9.8% of the senior physicians and 8.7% of the physicians in training suggested oral opioids as a treatment option, whereas intravenous opioids were suggested by 43.9% of the senior physicians and 21.7% of the physicians in training (p = 0.089). For subcutaneous application of opioids, the percentage of usage was significantly higher for the physicians in training than for the senior physicians (78.3% vs. 48.8%, p = 0.017, respectively).
CONCLUSION
CONCLUSIONS
The gold standard treatment for treating refractory dyspnea in patients with advanced lung cancer is opioids. Nevertheless, this pharmacological treatment option was not ranked as the most important. Discussing hypothetical cases of patients with advanced lung cancer and refractory dyspnea with experienced doctors as well as doctors at the beginning of their training may help improve symptom control for these patients.
Identifiants
pubmed: 35338391
doi: 10.1007/s00520-022-06996-6
pii: 10.1007/s00520-022-06996-6
pmc: PMC9135814
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5759-5768Informations de copyright
© 2022. The Author(s).
Références
Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J (2000) The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 19:357–362
doi: 10.1016/S0885-3924(00)00126-3
Dudgeon DJ, Lertzman M, Askew GR (2001) Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 21:373–379
doi: 10.1016/S0885-3924(01)00278-0
Higginson I, McCarthy M (1989) Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? J R Soc Med 82:264–267
doi: 10.1177/014107688908200507
Mercadante S, Casuccio A, Fulfaro F (2000) The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 20:104–112
doi: 10.1016/S0885-3924(00)00160-3
Simon ST, Bausewein C (2009) Management of refractory breathlessness in patients with advanced cancer. Wien Med Wochenschr 159:591–598
doi: 10.1007/s10354-009-0728-y
Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RKS, Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based C (2008) The management of dyspnea in cancer patients: a systematic review. Support Care Cancer 16:329–337
doi: 10.1007/s00520-007-0389-6
Jennings AL, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE (2002) A systematic review of the use of opioids in the management of dyspnoea. Thorax 57:939–944
doi: 10.1136/thorax.57.11.939
Hui D, Bohlke K, Bao T, Campbell TC, Coyne PJ, Currow DC, Gupta A, Leiser AL, Mori M, Nava S, Reinke LF, Roeland EJ, Seigel C, Walsh D, Campbell ML (2021) Management of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol 39:1389–1411
doi: 10.1200/JCO.20.03465
Chan K, Sham M, Tse D, Thorsen AB (2004) Palliative medicine in malignant respiratory diseases. In: Editor (ed)^(eds) Book Palliative medicine in malignant respiratory diseases. Oxford textbook of palliative medicine, 3rd ed. New York: Oxford University …, City
Arrieta O, Nunez-Valencia C, Reynoso-Erazo L, Alvarado S, Flores-Estrada D, Angulo LP, Onate-Ocana LF (2012) Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77:205–211
doi: 10.1016/j.lungcan.2012.02.005
Bausewein C, Booth S, Gysels M, Higginson I (2008) Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev CD005623
Kemp C (1997) Palliative care for respiratory problems in terminal illness. Am J Hosp Palliat Care 14:26–30
doi: 10.1177/104990919701400110
Thomas JR, von Gunten CF (2002) Clinical management of dyspnoea. Lancet Oncol 3:223–228
doi: 10.1016/S1470-2045(02)00713-1
Bruera E, MacEachern T, Ripamonti C, Hanson J (1993) Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906–907
doi: 10.7326/0003-4819-119-9-199311010-00007
Davis CL (1997) ABC of palliative care. Breathlessness, cough, and other respiratory problems. BMJ 315:931–934
doi: 10.1136/bmj.315.7113.931
Del Fabbro E, Dalal S, Bruera E (2006) Symptom control in palliative care—Part III: dyspnea and delirium. J Palliat Med 9:422–436
doi: 10.1089/jpm.2006.9.422
Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology 48:1234–1238
doi: 10.1212/WNL.48.5.1234
Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo JD, Buist AS (2003) Clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med 167:1142–1149
doi: 10.1164/rccm.200207-756WS
Congleton J, Muers MF (1995) The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 89:291–296
doi: 10.1016/0954-6111(95)90090-X
Cachia E, Ahmedzai SH (2008) Breathlessness in cancer patients. European Journal of Cancer 44: 1116–1123
Bruera E, Schoeller T, MacEachern T (1992) Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage 7:365–368
doi: 10.1016/0885-3924(92)90091-U
Cranston JM, Crockett A, Currow D (2008) Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev CD004769
Uronis HE, Abernethy AP (2008) Oxygen for relief of dyspnea: what is the evidence? Curr Opin Support Palliat Care 2:89–94
doi: 10.1097/SPC.0b013e3282ff0f5d
Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, Datla S, Dirksen CD, Johnson MJ, van Kuijk SMJ, Wouters EFM, Janssen DJA (2017) Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J 50
Schofield G, Baker I, Bullock R, Clare H, Clark P, Willis D, Gannon C, George R (2020) Palliative opioid use, palliative sedation and euthanasia: reaffirming the distinction. J Med Ethics 46:48–50
doi: 10.1136/medethics-2018-105256
Hadjiphilippou S, Odogwu S-E, Dand P (2014) Doctors’ attitudes towards prescribing opioids for refractory dyspnoea: a single-centred study. BMJ Support Palliat Care 4:190–192
doi: 10.1136/bmjspcare-2013-000565
Szajewska H (2014) Clinical practice guidelines: based on eminence or evidence? Ann Nutr Metab 64:325–331
doi: 10.1159/000365041
Simon ST, Koskeroglu P, Bausewein C (2012) Pharmacological therapy of refractory dyspnoea : a systematic literature review. Schmerz 26: 515–522
Borasio GD, Weltermann B, Voltz R, Reichmann H, Zierz S (2004) Attitudes towards patient care at the end of life. A survey of directors of neurological departments. Nervenarzt 75:1187–1193
doi: 10.1007/s00115-004-1751-2
Bendiane MK, Peretti-Watel P, Pegliasco H, Favre R, Galinier A, Lapiana J-M, Obadia Y (2005) Morphine prescription to terminally ill patients with lung cancer and dyspnea: French physicians’ attitudes. J Opioid Manag 1:25–30
doi: 10.5055/jom.2005.0008
Clemens KE, Quednau I, Klaschik E (2008) Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 11:204–216
doi: 10.1089/jpm.2007.0131
Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C (2003) Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327:523–528
doi: 10.1136/bmj.327.7414.523
Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Stemmer SM (2008) Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 26:2396–2404
doi: 10.1200/JCO.2007.15.5796
Cohen MH, Anderson AJ, Krasnow SH, Spagnolo SV, Citron ML, Payne M, Fossieck BE Jr (1991) Continuous intravenous infusion of morphine for severe dyspnea. South Med J 84:229–234
doi: 10.1097/00007611-199102000-00019
Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR (1990) Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6:7–11
doi: 10.1177/082585979000600303
Boyd KJ, Kelly M (1997) Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med 11:277–281
doi: 10.1177/026921639701100403
Zeppetella G (1997) Nebulized morphine in the palliation of dyspnoea. Palliat Med 11:267–275
doi: 10.1177/026921639701100402
Bruera E, Macmillan K, Pither J, MacDonald RN (1990) Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 5:341–344
doi: 10.1016/0885-3924(90)90027-H
Simon ST, Higginson IJ, Booth S, Harding R, Weingartner V, Bausewein C (2016) Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 10:CD007354
pubmed: 27764523
Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME (2006) Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 31:38–47
doi: 10.1016/j.jpainsymman.2005.06.009
Booth S, Kelly MJ, Cox NP, Adams L, Guz A (1996) Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 153:1515–1518
doi: 10.1164/ajrccm.153.5.8630595
Pohl G, Marosi C, Dieckmann K, Goldner G, Elandt K, Hassler M, Schemper M, Strasser-Weippl K, Nauck F, Gaertner J, Watzke H (2012) Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. Wiener Medizinische Wochenschrift 162:18–28
Rigg JR (1978) Ventilatory effects and plasma concentration of morphine in man. Br J Anaesth 50:759–765
doi: 10.1093/bja/50.8.759
LeGrand SB, Khawam EA, Walsh D, Rivera NI (2003) Opioids, respiratory function, and dyspnea. Am J Hosp Palliat Care 20:57–61
doi: 10.1177/104990910302000113
Walsh TD (1984) Opiates and respiratory function in advanced cancer. Recent Results Cancer Res 89:115–117
doi: 10.1007/978-3-642-82028-1_13